Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.01B | 943.55M | 791.01M | 704.87M | 578.57M |
Gross Profit | 680.83M | 627.82M | 541.24M | 306.82M | 250.74M |
EBITDA | 341.34M | 318.93M | 318.58M | 287.50M | 247.66M |
Net Income | 85.94M | -19.13M | -51.33M | -51.45M | -47.12M |
Balance Sheet | |||||
Total Assets | 4.68B | 4.58B | 4.58B | 4.81B | 4.89B |
Cash, Cash Equivalents and Short-Term Investments | 340.79M | 182.13M | 45.43M | 72.64M | 54.50M |
Total Debt | 39.32M | 1.26B | 2.25B | 2.26B | 2.30B |
Total Liabilities | 1.50B | 1.50B | 2.53B | 2.70B | 2.77B |
Stockholders Equity | 3.17B | 3.08B | 2.05B | 2.11B | 2.12B |
Cash Flow | |||||
Free Cash Flow | 278.56M | 142.50M | 29.94M | 85.20M | 91.86M |
Operating Cash Flow | 304.60M | 169.77M | 51.46M | 102.63M | 106.41M |
Investing Cash Flow | -76.56M | -27.27M | -61.52M | -17.43M | -444.33M |
Financing Cash Flow | 2.97M | 16.65M | -17.15M | -67.06M | 331.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $7.43B | 14.46 | 22.21% | 1.52% | 7.31% | -15.86% | |
75 Outperform | $6.81B | 29.18 | 24.70% | ― | 15.15% | 34.33% | |
74 Outperform | $5.19B | 15.51 | 21.63% | 1.34% | 3.39% | -16.78% | |
67 Neutral | $3.54B | 71.42 | 11.59% | ― | 47.78% | 74.61% | |
67 Neutral | $6.20B | 74.71 | 2.81% | ― | 17.14% | ― | |
65 Neutral | $8.55B | 21.11 | 11.57% | ― | 4.72% | -3.06% | |
56 Neutral | $6.50B | 15.33 | -29.08% | 6.35% | 11.10% | -32.94% |
On July 23, 2025, Waystar Holding Corp. announced a definitive agreement to acquire Iodine Software for $1.25 billion. This acquisition is expected to enhance Waystar’s AI capabilities in healthcare payments, expand its market by over 15%, and improve its financial profile. The merger will integrate Iodine’s AI-powered clinical intelligence software, which is trusted by many health systems, to reduce administrative costs and improve revenue cycle management. The transaction is anticipated to close by the end of 2025, subject to regulatory approvals.
The most recent analyst rating on (WAY) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Waystar Holding Corp. stock, see the WAY Stock Forecast page.
Waystar Holding Corp. announced changes to its board of directors following its annual meeting on June 4, 2025. The board expanded from ten to twelve members, appointing Aashima Gupta and Michael Roman as independent directors. Gupta, with a background in healthcare technology, and Roman, a former CEO of 3M, bring diverse expertise to the board. Additionally, the company’s stockholders approved an amendment to the Certificate of Incorporation and re-elected three directors, while also ratifying KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
The most recent analyst rating on (WAY) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Waystar Holding Corp. stock, see the WAY Stock Forecast page.
On May 9, 2025, Waystar Holding Corp.‘s Board approved a grant of performance stock units to CEO Matt Hawkins, tied to the company’s shareholder return relative to the S&P SmallCap 600 Information Technology sector over a four-year period. Additionally, the company plans to expand its board from ten to twelve directors, contingent on shareholder approval to amend its Certificate of Incorporation, with Aashima Gupta and Michael Roman nominated for new director roles.
The most recent analyst rating on (WAY) stock is a Buy with a $42.0000 price target. To see the full list of analyst forecasts on Waystar Holding Corp. stock, see the WAY Stock Forecast page.